Workshop | In Person
Event Title
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment
December 11, 2020
- Date:
- December 11, 2020
Overview
The purpose of the public workshop is to have scientific discussions on methods to evaluate the Opioid Analgesics Risk Evaluation and Mitigation Strategy (OA REMS).
The workshop has three main objectives:
- The first objective is to discuss what specific, measurable outcomes might demonstrate that training based on the Opioid Analgesics REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients With Pain (FDA Blueprint) is effective in educating prescribers and other health care providers (including pharmacists and nurses) involved in the treatment and monitoring of patients in pain about recommended pain management practices and the appropriate use of opioid analgesics.
- The second objective is to discuss the feasibility of conducting a study to specifically evaluate the effect of OA REMS-compliant continuing education (CE) on prescriber behavior and patient outcomes amidst the numerous concomitant strategies to combat the opioid crisis at the Federal, State, and local levels.
- The third objective is to discuss whether there might be suitable alternative study approaches to better understand the influence of CE, more broadly, on pain management practice and patient outcomes, if a study to directly measure the impact of REMS-compliant CE is thought to be infeasible.
To assist in the workshop discussion, FDA is making available an issues paper that provides a brief overview of the REMS background and challenges with evaluating the REMS education intervention.
DATE:
December 11, 2020, from 9:00 a.m. to 5 p.m.
LOCATION:
Virtual Meeting
MEETING MATERIALS
For optimal viewing use Chrome or Firefox web browsers
WEBCAST OF THE PUBLIC WORKSHOP:
Morning: Webcast Session
Afternoon: Webcast Session
COMMENTS ON THE PUBLIC WORKSHOP
Please refer to the Federal Register Notice on instructions for submitting either electronic or written comments on this public workshop. The deadline for comments is February 11, 2021.
FOR FURTHER INFORMATION CONTACT:
Paul Tran
Food and Drug Administration
10903 New Hampshire Avenue
Building 22, Room 4462
Silver Spring, Maryland 20993-0002
Phone: 301-796-9029
Email: OAREMS@fda.hhs.gov